Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Corcept Therapeutics Incorporated - Common Stock (NQ: CORT )

59.88 +4.56 (+8.25%)
Streaming Delayed Price Updated: 1:15 PM EST, Jan 21, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 347,459
Open 56.33
Bid (Size) 59.80 (1)
Ask (Size) 59.95 (4)
Prev. Close 55.31
Today's Range 55.90 - 59.92
52wk Range 20.87 - 62.22
Shares Outstanding 115,926,629
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Exploring NASDAQ:CORT's high growth characteristics.
Is CORCEPT THERAPEUTICS INC (NASDAQ:CORT) suited for high growth investing? 
Via Chartmill
Exploring the Growth Potential of NASDAQ:CORT as It Nears a Breakout.
CORCEPT THERAPEUTICS INC (NASDAQ:CORT), a strong growth stock, setting up for a breakout. 
Via Chartmill

Performance

YTD
+19.82%
+19.82%
1 Month
+17.63%
+17.63%
3 Month
+21.92%
+21.92%
6 Month
+73.20%
+73.20%
1 Year
+154.14%
+154.14%

More News

Read More
NASDAQ:CORT is not too expensive for the growth it is showing.
Via Chartmill
Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts.
Via Investor's Business Daily
Topics Artificial Intelligence Government
Exposures Artificial Intelligence Political
Corcept Submits New Drug Application for Relacorilant as a Treatment for Patients With Hypercortisolism
From Corcept Therapeutics Incorporated
Via Business Wire
Exploring high growth characteristics of CORCEPT THERAPEUTICS INC (NASDAQ:CORT).
Via Chartmill
NASDAQ:CORT, a strong growth stock, setting up for a breakout.
Via Chartmill
Investors should take note of NASDAQ:CORT, a growth stock that remains attractively priced.
Via Chartmill
Corcept’s Phase 3 Long-Term Extension Study of Relacorilant Demonstrated Durable Cardiometabolic Improvements in Patients with Hypercortisolism
From Corcept Therapeutics Incorporated
Via Business Wire
Corcept Therapeutics' FDA-Approved Korlym Hits Main Goal In Cushing's Syndrome Patients With Difficult-To-Control Diabetes
Via Benzinga
Corcept Announces Positive Results in Treatment Phase of CATALYST Trial in Patients With Hypercortisolism (Cushing’s Syndrome) and Difficult-to-Control Diabetes
From Corcept Therapeutics Incorporated
Via Business Wire
In the world of growth stocks, NASDAQ:CORT shines as a value proposition.
Via Chartmill
Earnings Preview: Corcept Therapeutics
Via Benzinga
Key Takeaways From Corcept Therapeutics Analyst Ratings
Via Benzinga
Corcept Announces Results From Phase 2 Study of Dazucorilant in Patients With Amyotrophic Lateral Sclerosis (ALS)
From Corcept Therapeutics Incorporated
Via Business Wire
NewAmsterdam Pharma Stock Hits 90-Plus RS Rating
Via Investor's Business Daily
For those who appreciate growth without the sticker shock, NASDAQ:CORT is worth considering.
Via Chartmill
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Corcept Therapeutics Announces Third Quarter Financial Results, Positive Results From Phase 3 GRADIENT Trial in Patients With Cushing’s Syndrome and Provides Corporate Update
From Corcept Therapeutics Incorporated
Via Business Wire
Is NASDAQ:CORT suited for high growth investing?
Via Chartmill
NASDAQ:CORT: a strong growth stock preparing for the next leg up?.
Via Chartmill
Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference Call
From Corcept Therapeutics Incorporated
Via Business Wire
Investors seeking growth at a reasonable cost should explore NASDAQ:CORT.
Via Chartmill
Corcept Therapeutics' Commercial Drug Korlym Sales Impress Despite Increased Competition, Analyst Boosts Price Forecast
Via Benzinga
Forecasting The Future: 6 Analyst Projections For Corcept Therapeutics
Via Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.